Download PDFPDF

Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Need of Live Attenuated Vaccine for Innate Immune Response Against Streptococcus pneumoniae; Targeting Netosis based Immune Response
    • Atif Amin Baig, Medical Researcher Faculty of Medicine, Universiti Sultan Zainal Abidin
    • Other Contributors:
      • Aina Shafiqah N Z, Postgraduate
      • Hanani M Ahmad Yusof, Lecturer
      • Yeo Chew Chieng, Researcher
      • Zahri M Khari, Scientist
      • Malik Amanov, Postgraduate
      • Adzim MK Rohin, Researcher
      • Alya Al Khateeb, Medical Lecturer
      • Hassanian Al Talib, Researcher
      • Majid Latif, Medical researcher
      • Zubaidi A Latif, Surgeon
      • Nordin Simbak, Surgeon

    he role of Neutrophil Extracellular Traps (NETs) in effectively trapping and destroying bacteria during a bacterial infections is a recent discovery. But certain bacterias, eg. Streptococcus Pneumoniae can escape traps by degrading chromatin fibers of NETs by surface exposed receptors and thus results in promoting bacterial spreading through the airway and into the bloodstream. Furthermore, Wartha and colleagues showed that S. pneumoniae evades NETs by a positive charge on its surface as a result of capsule expression and lipoteichoic acid d-alanylation. However, the mechanisms related to S. pneumoniae-induced NET formation remain unclear beside its degradation. The exact molecular mechanism of escaping NETs by S. pneumoniae is needed to be studied as per basic structural component degradation of NETs towards the pathogenesis and immunogenic response of S. pneumoniae against host defense mechanisms. Studying the exact molecular effect on the quantification and structure of NETs in infected neutrophils is expected to define specific pathogenic induction and destruction of NETs under the effect of specific genes in comparison with their mutants as live controls. The resultant mutants are also expected to give high immune response beside helping in understanding the basic mechanism of NETs in respect to specific genes. This could help in targeting the innate immune response at a more broader level beside multivalency of the vaccine will never be an issue.

    Conflict of Interest:
    None declared.